Literature DB >> 27835717

High Rates of Psychiatric Comorbidity in Narcolepsy: Findings From the Burden of Narcolepsy Disease (BOND) Study of 9,312 Patients in the United States.

Chad M Ruoff1, Nancy L Reaven2, Susan E Funk2, Karen J McGaughey3, Maurice M Ohayon4, Christian Guilleminault5, Jed Black6,7,8.   

Abstract

OBJECTIVE: To evaluate psychiatric comorbidity patterns in patients with a narcolepsy diagnosis in the United States.
METHODS: Truven Health Analytics MarketScan Research Databases were accessed to identify individuals ≥ 18 years of age with ≥ 1 ICD-9 diagnosis code(s) for narcolepsy continuously insured between 2006 and 2010 and non-narcolepsy controls matched 5:1 (age, gender, region, payer). Extensive subanalyses were conducted to confirm the validity of narcolepsy definitions. Narcolepsy subjects and controls were compared for frequency of psychiatric comorbid conditions (based on ICD-9 codes/Clinical Classification Software [CCS] level 2 categories) and psychiatric medication use.
RESULTS: The final population included 9,312 narcolepsy subjects and 46,559 controls (each group, mean age = 46.1 years; 59% female). All categories of mental illness were significantly more prevalent in patients with narcolepsy versus controls, with the highest excess prevalence noted for CCS 5.8 Mood disorders (37.9% vs 13.8%; odds ratio [OR] = 4.0; 95% CI, 3.8-4.2), CCS 5.8.2 Depressive disorders (35.8% vs 13.0%; OR = 3.9; 95% CI, 3.7-4.1), and CCS 5.2 Anxiety disorders (25.1% vs 11.9%; OR = 2.5; 95% CI, 2.4-2.7). Excess prevalence of anxiety and mood disorders (narcolepsy vs controls) was higher in younger age groups versus older age groups. Psychiatric medication usage was higher in the narcolepsy group versus controls in the following categories: selective serotonin reuptake inhibitors (36% vs 17%), anxiolytic benzodiazepines (34% vs 19%), hypnotics (29% vs 13%), serotonin-norepinephrine reuptake inhibitors (21% vs 6%), and tricyclic antidepressants (13% vs 4%) (all P values < .0001).
CONCLUSIONS: Narcolepsy is associated with significant comorbid psychiatric illness burden and higher psychiatric medication usage compared with the non-narcolepsy population. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 27835717     DOI: 10.4088/JCP.15m10262

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

Review 1.  Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Authors:  Steven T Szabo; Michael J Thorpy; Geert Mayer; John H Peever; Thomas S Kilduff
Journal:  Sleep Med Rev       Date:  2018-11-08       Impact factor: 11.609

Review 2.  Disrupted nighttime sleep and sleep instability in narcolepsy.

Authors:  Kiran Maski; Emmanuel Mignot; Giuseppe Plazzi; Yves Dauvilliers
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

Review 3.  pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Authors:  Noeen Sarfraz; David Okuampa; Hannah Hansen; Mark Alvarez; Elyse M Cornett; Juyeon Kakazu; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-05-30

Review 4.  Suicidality in sleep disorders: prevalence, impact, and management strategies.

Authors:  Christopher W Drapeau; Michael R Nadorff
Journal:  Nat Sci Sleep       Date:  2017-09-14

5.  Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.

Authors:  Richard K Bogan; Michael J Thorpy; Yves Dauvilliers; Markku Partinen; Rafael Del Rio Villegas; Nancy Foldvary-Schaefer; Roman Skowronski; Lihua Tang; Franck Skobieranda; Karel Šonka
Journal:  Sleep       Date:  2021-03-12       Impact factor: 5.849

6.  Different positron emission tomography findings in schizophrenia and narcolepsy type 1 in adolescents and young adults: a preliminary study.

Authors:  Wei-Chih Chin; Feng-Yuan Liu; Yu-Shu Huang; Ing-Tsung Hsiao; Chih-Huan Wang; Ying-Chun Chen
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

7.  Factors Associated with Depression and Sub-Dimension Symptoms in Adolescent Narcolepsy.

Authors:  Yang Yang; Chenyang Li; Long Zhao; Jing Li; Fang Han; Fulong Xiao
Journal:  Nat Sci Sleep       Date:  2021-07-06

8.  Attention impairments and ADHD symptoms in adult narcoleptic patients with and without hypocretin deficiency.

Authors:  Marco Filardi; Fabio Pizza; Lorenzo Tonetti; Elena Antelmi; Vincenzo Natale; Giuseppe Plazzi
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

9.  Can a Peer Support the Process of Self-Management in Narcolepsy? A Qualitative Narrative Analysis of a Narcoleptic Patient.

Authors:  Christian Franceschini; Chiara Fante; Marco Filardi; Maria Claudia Folli; Francesca Brazzi; Fabio Pizza; Anita D'Anselmo; Francesca Ingravallo; Elena Antelmi; Giuseppe Plazzi
Journal:  Front Psychol       Date:  2020-07-07

10.  Concomitant atopic dermatitis and narcolepsy type 1: psychiatric implications and challenges in management.

Authors:  Justin Chin; Craig Bearison; Nanette Silverberg; Mary Lee Wong
Journal:  Gen Psychiatr       Date:  2019-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.